Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
As healthcare costs continue to rise, accurate cost-effectiveness estimates are crucial. However, estimating the costs and outcomes of different interventions is complicated by uncertainty.
In model-based health economic evaluations (HEEs), uncertainty can arise from limited data, methodological limitations, and variability in clinical outcomes.
A recent review identified 80 methods for identifying, analyzing, and communicating uncertainty in HEEs. Quantifying uncertainty wherever possible is crucial to ensure accurate and unbiased cost-effectiveness estimates, ultimately leading to optimal allocation of healthcare resources
Recent Posts
Safeguarding Access: Navigating Pharmaceutical Cost Pressures in Portugal
Pharmaceutical cost pressures are mounting in Portugal, with industry leaders warning that price increases for certain medicines appear inevitable in the medium term despite the government’s commitment to strict controls in the 2026 annual review.
Global Cost Drivers Threaten Generic...
Inequality-Adjusted ICER: Enhancing Cost-Effectiveness in Health Technology Evaluation
The inequality-adjusted ICER offers a practical way to embed explicit trade-offs between maximising total population health and reducing health inequality directly into cost-effectiveness analysis. By dividing the conventional ICER by an inequality-adjusted ICER, analysts derive a health inequali...
Semaglutide Distribution Flexibility: EMA Approves Room Temperature Delivery for Wegovy®
The European Medicines Agency (EMA) has granted an important update to the product information for Wegovy (semaglutide), introducing semaglutide distribution flexibility that allows controlled-temperature delivery at up to 30°C for up to 48 hours during the final leg from pharmacies to patients. ...